RAD June 2024 Abstracts and Posters
697 Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data
ta Mark Lebwohl, Emma Yue, Whitney Krueger, Brian Berman, Christopher G Bunick, Todd Schlesinger, Ayman Grada
698 Impact of amlitelimab (an anti-OX40 Ligand antibody) on clinical outcome assessments for atopic dermatitis: results from the 52-week STREAM-AD phase 2b study in adults with moderate-to-severe atopic dermatitis
Andrew Blauvelt; Raj Chovatiya; Joseph F. Merola; Stephan Weidinger; Ken Igawa; Efstathios Zikos; Christine Weber; Jennifer Wang; Cori Gra
699 Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study
Arash Mostaghimi, April W Armstrong, Ayman Grada, Ahmed M Soliman, Chao Li, Claire C Bristow, Dawid Lipiszko, Jonathan I Silverberg, Naiem T Issa, Christopher G Bunick
700 Characterization of atopic dermatitis medication use before and during pregnancy in the United States
Laura E. Dodge, Shiyao Gao, Sarah-Jo Sinnott, Andrea F. Marcus, Ashley Howell, Aziza Jamal-Allial, Jui-Ting Hsiung, Maria Guzman, Florence T. Wang
701 Dupilumab efficacy and safety up to 2 years in children aged 6 months to 5 years with atopic dermatitis
Amy S Paller, Eric L Simpson , Elaine C Siegfried, Michael J Cork, Peter D Arkwright, Andreas Pinter, Ariane Dubost-Brama, Elizabeth Laws, Zhen Chen, Ashish Bansal, Randy Prescilla, Tien V. Nguyen
702 IMG-007, a nondepleting OX40 monoclonal antibody with an extended half-life, improves skin lesions in adults with moderate-to-severe atopic dermatitis: interim results from a phase 2a trial
Yancong Shen, Zi Lin, Chongtian Guo, Aswin Nair, Yufang Lu, Jonathan I. Silverberg
703 Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with moderate and/or more extensive atopic dermatitis: subgroup analysis from the TRuE-AD3 study
Lawrence F. Eichenfield, MD, April W. Armstrong, MD, MPH, Linda F. Stein Gold, MD, PhD, Andrea L. Zaenglein, MD, Lara Wine Lee, MD, PhD, Kanwaljit K. Brar, MD, Joel C. Joyce, MD, Kristen E. Holland, MD, Brett Angel, MD, Daniel Sturm, PharmD, Qian Li, PhD, Eric L. Simpson, MD, MCR
704 Effectiveness of atopic dermatitis patient education programs – a systematic review and meta-analysis
Luis F. Andrade, BSc; Parsa Abdi, BASc; Kayla D. Mashoudy BS; Amritpal Kooner MS; Ashley Egler BS, Rebecca Urbonas BS, Aaron Smith BS, Gil Yosipovitch, MD
705 Patient preferences for atopic dermatitis treatment profiles: results from a discrete choice experiment
Matthew Quaife, Sarah Mulnick, Harrison Clarke, Kerry Noonan, Gaelle Le-Bagousse-Bego, Debra Sierka, El-Bdaoui Haddad, Raj Chovatiya
706 Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study
Jonathan I Silverberg, Brian M Calimlim, Zelma C Chiesa Fuxench, Katherine Altman, Arielle G Bensimon, Jiaxuan Liu, Christopher G Bunick